PYODERMA GANGRENOSUM
Clinical trials for PYODERMA GANGRENOSUM explained in plain language.
Never miss a new study
Get alerted when new PYODERMA GANGRENOSUM trials appear
Sign up with your email to follow new studies for PYODERMA GANGRENOSUM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug hopes to heal devastating skin ulcers in rare disease
Disease control Recruiting nowThis study tests if spesolimab can close painful skin ulcers in adults with pyoderma gangrenosum, a rare inflammatory condition. About 90 participants will receive either the drug or a placebo, along with oral steroids for the first 8 weeks. The main goal is complete ulcer closur…
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated May 17, 2026 06:17 UTC
-
New hope for rare skin ulcers: guselkumab trial launches
Disease control Recruiting nowThis study tests if guselkumab can heal painful skin ulcers in adults with pyoderma gangrenosum, a rare condition. 17 participants will receive the drug and be checked at 6, 16, and 32 weeks. The main goal is complete wound healing by week 32.
Matched conditions: PYODERMA GANGRENOSUM
Phase: PHASE2 • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated May 11, 2026 20:53 UTC